Noxxon Pharma AG – Product Pipeline Review

Global Markets Direct’s, ‘Noxxon Pharma AG – Product Pipeline Review – 2016’, provides an overview of the Noxxon Pharma AG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Noxxon Pharma AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Noxxon Pharma AG

The report provides overview of Noxxon Pharma AG including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Noxxon Pharma AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Noxxon Pharma AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Noxxon Pharma AG’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Noxxon Pharma AG

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Noxxon Pharma AG’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Noxxon Pharma AG Snapshot 5

Noxxon Pharma AG Overview 5

Key Facts 5

Noxxon Pharma AG - Research and Development Overview 6

Key Therapeutic Areas 6

Noxxon Pharma AG - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Noxxon Pharma AG - Pipeline Products Glance 11

Noxxon Pharma AG - Clinical Stage Pipeline Products 11

Phase II Products/Combination Treatment Modalities 11

Phase I Products/Combination Treatment Modalities 12

Noxxon Pharma AG - Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Noxxon Pharma AG - Drug Profiles 14

emapticap pegol - Drug Profile 14

Product Description 14

Mechanism Of Action 14

R&D Progress 14

lexaptepid pegol - Drug Profile 16

Product Description 16

Mechanism Of Action 16

R&D Progress 16

NOXD-19 - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

NOXD-20 - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

NOXD-21 - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

NOXG-15 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

NOXG-16 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

NOXL-41 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

NOXS-93 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

olaptesed pegol - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Noxxon Pharma AG - Pipeline Analysis 29

Noxxon Pharma AG - Pipeline Products by Target 29

Noxxon Pharma AG - Pipeline Products by Route of Administration 30

Noxxon Pharma AG - Pipeline Products by Molecule Type 31

Noxxon Pharma AG - Pipeline Products by Mechanism of Action 32

Noxxon Pharma AG - Dormant Projects 33

Noxxon Pharma AG - Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Appendix 35

Methodology 35

Coverage 35

Secondary Research 35

Primary Research 35

Expert Panel Validation 35

Contact Us 35

Disclaimer 36

List of Tables

List of Tables

Noxxon Pharma AG, Key Facts 5

Noxxon Pharma AG – Pipeline by Indication, 2016 8

Noxxon Pharma AG – Pipeline by Stage of Development, 2016 9

Noxxon Pharma AG – Monotherapy Products in Pipeline, 2016 10

Noxxon Pharma AG – Phase II, 2016 11

Noxxon Pharma AG – Phase I, 2016 12

Noxxon Pharma AG – Preclinical, 2016 13

Noxxon Pharma AG – Pipeline by Target, 2016 29

Noxxon Pharma AG – Pipeline by Route of Administration, 2016 30

Noxxon Pharma AG – Pipeline by Molecule Type, 2016 31

Noxxon Pharma AG – Pipeline Products by Mechanism of Action, 2016 32

Noxxon Pharma AG – Dormant Developmental Projects,2016 33

Noxxon Pharma AG, Subsidiaries 34

List of Figures

List of Figures

Noxxon Pharma AG – Pipeline by Top 10 Indication, 2016 7

Noxxon Pharma AG – Pipeline by Stage of Development, 2016 9

Noxxon Pharma AG – Monotherapy Products in Pipeline, 2016 10

Noxxon Pharma AG – Pipeline by Target, 2016 29

Noxxon Pharma AG – Pipeline by Route of Administration, 2016 30

Noxxon Pharma AG – Pipeline by Molecule Type, 2016 31

Noxxon Pharma AG – Pipeline Products by Mechanism of Action, 2016 32

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports